Biomaterial Database

Control of luteal function during pregnancy: antiluteolytic and luteotropic properties of the developing mouse conceptus. 1982

E S Critser, and P J Savage, and J J Rutledge, and L R French

Eight experiments were conducted to examine the influence of the conceptus on luteal function in mice. In uterine intact pseudopregnant mice, exogenous treatment with placental extracts or pregnant mouse plasma from Day 8 or Day 10 of gestation did not prolong the life span of the corpora lutea (CL). The interestrous interval (IEI) of hysterectomized pseudopregnant mice was extended by treatment with Day 10 placental extract and was accompanied by elevated plasma progesterone, consistent with the luteotropic nature of the Day 10 conceptus. The IEI of uterine intact pseudopregnant mice was prolonged by the presence of ectopically developing blastocysts and was further extended by a treatment with Day 10 placental extracts but not by treatment with Day 8 placental extracts. Although the ectopic blastocyst delayed the effect of the uterine luteolytic mechanism, there was no indication of luteotropic activity: the ectopic blastocysts were unable to activate the CL of the estrous cycle. In addition, plasma progesterone and 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM) were measured in pseudopregnant, hysterectomized pseudopregnant and pregnant mice on Day 2 through 13 post-mating. The results of these experiments suggest a two-step mechanism in prolonging luteal function during pregnancy which involves two different substances. This mechanism involves an initial signal from the conceptus which blocks the uterine luteolytic mechanism and a subsequent luteotropic stimulus from the Day 10 conceptus which extends luteal life span to approximately the length of gestation.

UI	MeSH Term	Description	Entries
D008954	Models, Biological	Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.	Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010920	Placenta	A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES).	Placentoma, Normal,Placentome,Placentas,Placentomes
D011247	Pregnancy	The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	Gestation,Pregnancies
D011255	Pregnancy Maintenance	Physiological mechanisms that sustain the state of PREGNANCY.	Maintenance, Pregnancy,Maintenances, Pregnancy,Pregnancy Maintenances
D011271	Pregnancy, Ectopic	A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (>96%) occur in the FALLOPIAN TUBES, known as TUBAL PREGNANCY. They can be in other locations, such as UTERINE CERVIX; OVARY; and abdominal cavity (PREGNANCY, ABDOMINAL).	Ectopic Pregnancy,Pregnancy, Extrauterine,Ectopic Pregnancies,Extrauterine Pregnancies,Extrauterine Pregnancy,Pregnancies, Ectopic,Pregnancies, Extrauterine
D011374	Progesterone	The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.	Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D011460	Prostaglandins F	(9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics.	PGF
D011555	Pseudopregnancy	An acyclic state that resembles PREGNANCY in that there is no ovarian cycle, ESTROUS CYCLE, or MENSTRUAL CYCLE. Unlike pregnancy, there is no EMBRYO IMPLANTATION. Pseudopregnancy can be experimentally induced to form DECIDUOMA in the UTERUS.	Pseudocyesis,Pseudopregnancies
D001755	Blastocyst	A post-MORULA preimplantation mammalian embryo that develops from a 32-cell stage into a fluid-filled hollow ball of over a hundred cells. A blastocyst has two distinctive tissues. The outer layer of trophoblasts gives rise to extra-embryonic tissues. The inner cell mass gives rise to the embryonic disc and eventual embryo proper.	Embryo, Preimplantation,Blastocysts,Embryos, Preimplantation,Preimplantation Embryo,Preimplantation Embryos
D003338	Corpus Luteum	The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE.	Corpora Lutea,Lutea, Corpora